{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Zhuang P"],"funding":["Young Elite Scientists Sponsorship Program by CAS","Natural Science Foundation of Zhejiang Province","National Natural Science Foundation of China"],"pagination":["52"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC12905938"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["25(1)"],"pubmed_abstract":["<h4>Background</h4>Carotid plaques result from a blockage or narrowing of carotid arteries associated with severe atherosclerotic cardiovascular diseases. We aimed to assess the effect of marine n-3 fatty acid supplementation on carotid plaques among patients with diabetes and whether the effect was modified by genetics.<h4>Methods</h4>In this 14 month double-blind, randomized controlled trial, 415 patients with type 2 diabetes (T2D) were randomly assigned to receive high-dose (3.0 g/day) or low-dose (1.5 g/day) marine n-3 fatty acids (fish oil) or placebo (refined olive oil). The primary outcome was the prevalence of carotid plaques. Secondary outcomes included changes in NMR-derived lipoprotein subclasses. Genetic interactions with the supplementation were also explored.<h4>Results</h4>3"],"journal":["Cardiovascular diabetology"],"pubmed_title":["Marine n-3 fatty acid treatment for carotid plaques in patients with type 2 diabetes."],"pmcid":["PMC12905938"],"funding_grant_id":["2022QNRC001","32202057","81773419","LY23C200007"],"pubmed_authors":["Zhang F","Wang A","Wan X","Zhang L","Jiao J","Wu F","Liu X","Chen W","Ao Y","Wu S","Jia W","Gu J","Wu Y","Yu X","Wu X","Zhuang P","Li H","Zhu F","Zheng W","Lan X","Tong W","Li Y","Meng D","Zhu L","Zhang Y","Tian Y","Ye H","Shi H"],"additional_accession":[]},"is_claimable":false,"name":"Marine n-3 fatty acid treatment for carotid plaques in patients with type 2 diabetes.","description":"<h4>Background</h4>Carotid plaques result from a blockage or narrowing of carotid arteries associated with severe atherosclerotic cardiovascular diseases. We aimed to assess the effect of marine n-3 fatty acid supplementation on carotid plaques among patients with diabetes and whether the effect was modified by genetics.<h4>Methods</h4>In this 14 month double-blind, randomized controlled trial, 415 patients with type 2 diabetes (T2D) were randomly assigned to receive high-dose (3.0 g/day) or low-dose (1.5 g/day) marine n-3 fatty acids (fish oil) or placebo (refined olive oil). The primary outcome was the prevalence of carotid plaques. Secondary outcomes included changes in NMR-derived lipoprotein subclasses. Genetic interactions with the supplementation were also explored.<h4>Results</h4>3","dates":{"release":"2026-01-01T00:00:00Z","publication":"2026 Jan","modification":"2026-07-15T21:31:00.115Z","creation":"2026-07-09T10:14:06.882Z"},"accession":"S-EPMC12905938","cross_references":{"pubmed":["41559698"],"doi":["10.1186/s12933-026-03082-7"]}}